NEW YORK, June 29, 2016 /PRNewswire/ --
The Biotech industry has seen pressure with pricing, policies, and economic uncertainties, but still it continues to present a number of great trades. Stock-Callers.com reviews the performances of the following companies at yesterday's close and see if they are worthy of consideration: Cellectar Biosciences Inc. (NASDAQ: CLRB), Xenoport Inc. (NASDAQ: XNPT), Rexahn Pharmaceuticals Inc. (NYSE: RNN), and Tesaro Inc. (NASDAQ: TSRO). Learn more about these stocks and receive your complimentary trade alerts at:
To access Stock-Callers.com full PDF Research Packages for free, please visit the links below.
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
CLRB Research Package: http://stock-callers.com/registration/?symbol=CLRB
XNPT Research Package: http://stock-callers.com/registration/?symbol=XNPT
RNN Research Package: http://stock-callers.com/registration/?symbol=RNN
TSRO Research Package: http://stock-callers.com/registration/?symbol=TSRO
Madison, Wisconsin headquartered clinical stage biopharmaceutical Company, Cellectar Biosciences Inc.'s stock climbed 2.46% and finished Tuesday's trading session at $3.33. A total volume of 205,145 shares was traded. In the last one month, the stock has advanced 10.26%. The Company's shares are trading above their 50-day moving average by 29.05%. Moreover, shares of Cellectar Biosciences, which engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer, have a Relative Strength Index (RSI) of 53.18.
On Tuesday, shares in Santa Clara, California-based biopharmaceutical Company, Xenoport Inc., recorded a trading volume of 467,311 shares, and ended the session 0.14% higher at $7.02. The stock has gained 59.91% in the previous three months and 27.87% on an YTD basis. The Company's shares are trading 22.44% above their 50-day moving average and 34.62% above their 200-day moving average. Furthermore, shares of Xenoport, which focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders in the U.S., have an RSI of 78.69.
Shares in Rockville, Maryland-based clinical stage biopharmaceutical Company, Rexahn Pharmaceuticals Inc., closed the day at $0.26, gaining 3.14%. The stock recorded a trading volume of 430,125 shares. The Company's shares are trading 10.51% below their 50-day moving average. Additionally, shares in Rexahn Pharmaceuticals, which discovers, develops, and commercializes treatments for cancer, have an RSI of 38.65.
At the closing bell yesterday, shares in Waltham, Massachusetts headquartered oncology-focused biopharmaceutical Company, Tesaro Inc. ended 8.37% lower at $37.21. A total volume of 1.30 million shares was traded, which was higher than their three months average volume of 579,600 shares. The stock is trading below its 50-day moving average by 13.86%. Furthermore, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the U.S. and globally, have an RSI of 37.04.
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA